米托蒽醌和VP_(16)治疗难治性复发性急性白血病临床治疗观察  

CLINICAL OBSERVATION OF RRAL WITH MIX AND VP_(16)

作　　者：潘理明[1] 朱薇波[1] 刘欣[1] 余自强[1] 孙自敏[1] 蔡晓燕[1] 

机构地区：[1]安徽省立医院,安徽合肥230001

出　　处：《白血病》2000年第1期15-16,共2页

摘　　要：目的 :探索难治性复发性急性白血病 ( RRAL)的治疗。方法 :应用米托蒽醌 ( 3 d)和 VP1 6( 5 d)再诱导治疗 RRAL 2 7例 ,在化疗的第 7天 ,根据原始细胞下降指数 ,决定是否再增加米托蒽醌。结果 :15 / 2 7例 CR,CRR5 5 .6% ;6/ 2 7例 PR,占 2 2 .2 % ,总有效率 77.8%。CR的 15例中 ,一疗程 CRR占 93 .3 %。结论 :以米托蒽醌为主的联合化疗治疗 RRAL副作用轻 ,对 M3 复发者仍有效 。Objective:RRAL remains one of the difficult problems in therapy. Such patients show very poor immune functions after long term chemical therapy for years. Drug resistance to various extent occurs to the patients with RRAL,because they have been feeble and used muliti medication therapy.Methods:27 patients with RRAL were reinduceablly treated with combined chemical therapy of home made Mix and VP 16 form Oct.1991 to Oct. 1998.According to drop indexes of primitive cells,detemination was made on whether to readd Mix on the 7th day of chemical therapy.Results: of 27 patients, CR accounted for 15(55.6%) and PR accounted for 6(22.2%),effective rate totaling 77.8%,of 15 cases of CR,once therapy period CRR accounted for 93.3%.Conclusions:Although Mix was dominant in combined therapy for RRAL in literatures,therapy effects varied from person to person.The therapy effect in this report was higher than that in other chemical therapy,especially for CR patients side effect and was still effective for reoccurrent M 3 patients.

关 键 词：白血病 治疗 急性 米托蒽醌 

分 类 号：R733.71[医药卫生—肿瘤]